IL234892B - A novel cholesterol metabolite,5-cholesten, 3β-25-diol. disulfate(25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis - Google Patents

A novel cholesterol metabolite,5-cholesten, 3β-25-diol. disulfate(25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis

Info

Publication number
IL234892B
IL234892B IL234892A IL23489214A IL234892B IL 234892 B IL234892 B IL 234892B IL 234892 A IL234892 A IL 234892A IL 23489214 A IL23489214 A IL 23489214A IL 234892 B IL234892 B IL 234892B
Authority
IL
Israel
Prior art keywords
25hcds
cholesten
disulfate
hyperlipidemia
atherosclerosis
Prior art date
Application number
IL234892A
Other languages
English (en)
Hebrew (he)
Original Assignee
Virgina Commonwealth Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virgina Commonwealth Univ filed Critical Virgina Commonwealth Univ
Publication of IL234892B publication Critical patent/IL234892B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14Details; Accessories therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/003Normal steroids containing one or more sulfur atoms not belonging to a hetero ring the S atom directly linked to a ring carbon atom of the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL234892A 2012-04-12 2014-09-28 A novel cholesterol metabolite,5-cholesten, 3β-25-diol. disulfate(25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis IL234892B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261623203P 2012-04-12 2012-04-12
US201261623414P 2012-04-12 2012-04-12
PCT/US2013/031861 WO2013154752A1 (en) 2012-04-12 2013-03-15 A NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3β-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS

Publications (1)

Publication Number Publication Date
IL234892B true IL234892B (en) 2019-02-28

Family

ID=49328028

Family Applications (1)

Application Number Title Priority Date Filing Date
IL234892A IL234892B (en) 2012-04-12 2014-09-28 A novel cholesterol metabolite,5-cholesten, 3β-25-diol. disulfate(25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis

Country Status (20)

Country Link
US (6) US20150072962A1 (https=)
EP (2) EP3239163A1 (https=)
JP (4) JP6125610B2 (https=)
KR (1) KR102180485B1 (https=)
CN (2) CN106083976B (https=)
AU (2) AU2013246435B2 (https=)
BR (1) BR112014025081B1 (https=)
CA (1) CA2867694C (https=)
DK (1) DK2836502T3 (https=)
EA (1) EA026683B1 (https=)
ES (1) ES2641841T3 (https=)
HU (1) HUE035073T2 (https=)
IL (1) IL234892B (https=)
IN (1) IN2014KN02366A (https=)
MX (1) MX357046B (https=)
PL (1) PL2836502T3 (https=)
PT (1) PT2836502T (https=)
SI (1) SI2836502T1 (https=)
WO (1) WO2013154752A1 (https=)
ZA (1) ZA201406981B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
EA026683B1 (ru) * 2012-04-12 2017-05-31 Вирджиния Коммонвелт Юниверсити МЕТАБОЛИТ ХОЛЕСТЕРИНА ДИСУЛЬФАТ 5-ХОЛЕСТЕН-3β,25-ДИОЛА (25HCDS) ДЛЯ ТЕРАПИИ НАРУШЕНИЙ ОБМЕНА ВЕЩЕСТВ, ГИПЕРЛИПИДЕМИИ, ДИАБЕТА, ЖИРОВЫХ БОЛЕЗНЕЙ ПЕЧЕНИ И АТЕРОСКЛЕРОЗА
PL3639828T3 (pl) * 2013-12-24 2022-05-02 Virginia Commonwealth University Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby
TWI547280B (zh) * 2014-04-24 2016-09-01 長弘生物科技股份有限公司 穩定醫藥組合物
US10238664B2 (en) 2014-07-09 2019-03-26 Duke University Compositions and methods for the repair of myelin
CN107106576A (zh) * 2014-10-10 2017-08-29 弗吉尼亚联邦大学 用于因减弱的瘦蛋白活性和脂质贮积障碍中的至少一种导致的障碍的疗法的氧化胆固醇硫酸酯类
JP6784963B2 (ja) * 2014-12-24 2020-11-18 国立大学法人京都大学 ビタミンd3誘導体及びその薬学的用途
US20200222430A1 (en) * 2016-08-02 2020-07-16 Durect Corporation Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride
EP3494125B1 (en) 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
CA3031211A1 (en) * 2016-08-02 2018-02-08 Virginia Commonwealth University Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesions
US11458146B2 (en) 2017-01-13 2022-10-04 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
KR101892577B1 (ko) 2017-04-21 2018-08-28 부산대학교 산학협력단 레블라스타틴 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 조성물
CN107286160A (zh) * 2017-06-05 2017-10-24 毛佳婧 一种抗肝炎药物的哌啶并吡啶并吡唑‑锌配合物的制备方法
RU2020110253A (ru) * 2017-08-31 2021-09-30 Ариэль Сайентифик Инновейшнз Лтд Экстракт s. spinosum для лечения жировой болезни печени
BR112022005039A2 (pt) * 2019-09-30 2022-06-21 Durect Corp Tratamento de hepatite alcoólica
EP4171573A4 (en) * 2020-06-26 2025-04-09 Durect Corporation USE OF OXYGENATED CHOLESTEROL SULFATES FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS, NEURODEGENERATIVE DISEASES AND ADDICTION
CN112294827B (zh) * 2020-11-12 2021-12-24 四川大学华西医院 5-胆甾烯 -3β-醇硫酸酯盐的用途
KR102732697B1 (ko) 2021-10-29 2024-11-25 부산대학교 산학협력단 크산틴 유도체를 유효성분으로 포함하는 죽상동맥경화증 예방 또는 치료용 약학적 조성물
WO2024008614A1 (en) * 2022-07-08 2024-01-11 Société des Produits Nestlé S.A. Use of 25-hydroxycholesterol for diabetic treatment and/or prevention

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL146223A0 (en) * 1999-04-30 2002-07-25 Arch Dev Corp Steroid derivatives
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
CA2637884A1 (en) 2006-02-13 2007-08-23 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US8003795B2 (en) 2007-06-22 2011-08-23 Cvi Pharmaceuticals Limited Compounds and compositions for reducing lipid levels
WO2011077245A2 (en) * 2009-12-23 2011-06-30 Fondazione Centro San Raffaele Del Monte Tabor Compositions
EA026683B1 (ru) * 2012-04-12 2017-05-31 Вирджиния Коммонвелт Юниверсити МЕТАБОЛИТ ХОЛЕСТЕРИНА ДИСУЛЬФАТ 5-ХОЛЕСТЕН-3β,25-ДИОЛА (25HCDS) ДЛЯ ТЕРАПИИ НАРУШЕНИЙ ОБМЕНА ВЕЩЕСТВ, ГИПЕРЛИПИДЕМИИ, ДИАБЕТА, ЖИРОВЫХ БОЛЕЗНЕЙ ПЕЧЕНИ И АТЕРОСКЛЕРОЗА

Also Published As

Publication number Publication date
BR112014025081A2 (pt) 2018-05-08
PT2836502T (pt) 2017-10-27
JP2015512937A (ja) 2015-04-30
ES2641841T3 (es) 2017-11-14
DK2836502T3 (en) 2017-10-23
ZA201406981B (en) 2016-05-25
KR102180485B1 (ko) 2020-11-18
AU2017268646B2 (en) 2019-07-11
JP6125610B2 (ja) 2017-05-10
EP3239163A1 (en) 2017-11-01
BR112014025081B1 (pt) 2020-12-08
CA2867694A1 (en) 2013-10-17
SI2836502T1 (sl) 2017-11-30
AU2013246435B2 (en) 2017-10-05
US20180127457A1 (en) 2018-05-10
PL2836502T3 (pl) 2018-01-31
EA201491859A1 (ru) 2015-02-27
US20150072962A1 (en) 2015-03-12
US20210238219A1 (en) 2021-08-05
JP2021138713A (ja) 2021-09-16
US20190135856A1 (en) 2019-05-09
WO2013154752A1 (en) 2013-10-17
US20160355544A1 (en) 2016-12-08
CA2867694C (en) 2021-08-31
EP2836502B1 (en) 2017-08-02
CN104220450A (zh) 2014-12-17
HK1202294A1 (en) 2015-09-25
US20200157140A1 (en) 2020-05-21
CN106083976B (zh) 2018-02-09
CN106083976A (zh) 2016-11-09
EP2836502A4 (en) 2015-08-19
HUE035073T2 (en) 2018-05-02
EP2836502A1 (en) 2015-02-18
IN2014KN02366A (https=) 2015-05-01
AU2017268646A1 (en) 2017-12-21
CN104220450B (zh) 2016-07-06
JP2017160213A (ja) 2017-09-14
MX2014012324A (es) 2015-05-11
AU2013246435A1 (en) 2014-10-16
EA026683B1 (ru) 2017-05-31
KR20150013520A (ko) 2015-02-05
JP2019089777A (ja) 2019-06-13
MX357046B (es) 2018-06-22

Similar Documents

Publication Publication Date Title
IL234892B (en) A novel cholesterol metabolite,5-cholesten, 3β-25-diol. disulfate(25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty liver diseases and atherosclerosis
WO2012118769A9 (en) Immersive display experience
GB2496799B (en) A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
GB2489658B (en) Tablet press
GB201119861D0 (en) Method of operating a heterogeneous computer system
IL235058A0 (en) Pharmaceutical combinations for the treatment of metabolic disorders
ZA201400326B (en) Bouillon tablet process
PT2739750T (pt) Doença cardiovascular
GB201110862D0 (en) Controlling the operation of server computers
EP2721514A4 (en) AUTOMATION SERVICES FOR A PRESENTATION SOFTWARE
EP2664981B8 (en) Press-type input device
GB2491100B (en) Operating a server computer
HK1206824A1 (en) Display mechanism, for timepiece
EM13032340001S (pl) Urządzenia wejściowe do komputerów
EM13032340002S (lv) Datoru ievadierīces
AU2012902788A0 (en) Method of treating glucose metabolism disorders
GB201205959D0 (en) Software patent application for internet pos solution
EM13031010005S (da) Perifere enheder til computere
EM13031010001S (cs) počítačová periferní zařízení
EM13031010006S (nl) Computerrandapparatuur
EM13031010003S (da) Perifere enheder til computere
EM13031010007S (lv) Datoru perifērijas ierīces
EM13031010004S (en) Computer peripheral devices
EM13031010002S (fi) Tietokoneiden oheislaitteet
AU2012904468A0 (en) Computer implemented methods, programs and framework for providing a distributed multi-player chance-based game

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed